Project Navigator
Let's try to finance it!
A new, user friendly way, to get information about current clinical trials available to prostate cancer patients.
Tags
177Lu-PSMA-617 abiraterone abiraterone acetate ADC ADT AI ai in healthcare antibody-drug conjugate apalutamide ATM B7-H3 bispecific antibody bone metastases bone metastasis BRCA BRCA2 cancer immunotherapy CAR-T clinical trial crispr darolutamide docetaxel drug repurposing drug resistance enzalutamide EZH2 inhibitor HRR immunotherapy mcrpc metastatic hormone-sensitive prostate cancer mHSPC mRNA NEPC neuroendocrine prostate cancer oncolytic virus PARP inhibitor Pluvicto prostate cancer protac PSMA radioligand therapy radiopharmaceuticals real-world data T-cell therapy theranostics
Latest Posts
- Newsletter 11/2026 March 15, 2026
- Blood Lipid Profiles in Metastatic Prostate Cancer: A Window into Tumor Metabolism and Response to Enzalutamide March 14, 2026
- Organoids from Routine TUR‑P Samples: A Personalized Platform for Prostate Cancer Therapy Testing March 13, 2026
- Estrogen‑Based Androgen Suppression Plus ARSI in Prostate Cancer: A Phase 2 Quality‑of‑Life Trial March 13, 2026
UPDATE: AO-252, a New First-in-Class Brain-Penetrating TACC3 Inhibitor for Prostate Cancer
/in Clinical Trial, Metastatic, Phase 1/by MaxA new drug called AO-252, an oral inhibitor of TACC3, is now in phase 1 trials specifically testing it against prostate cancer among other solid tumors. It smartly blocks TACC3’s key partnerships with proteins like KIFC1, clathrin, BRCA1, and others, triggering mitotic disasters and halting growth in both lab models and early patients (some saw tumors […]
GSK5764227: An Antibody-Drug Conjugate Targeting B7-H3 Enters Phase 1/2 Trial
/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxGSK5764227 represents a promising advancement in treating metastatic castration-resistant prostate cancer (mCRPC). This antibody-drug conjugate targets B7-H3, a protein overexpressed on prostate cancer cells, delivering a topoisomerase I inhibitor payload directly to tumors while minimizing damage to healthy tissues. Early data from broader solid tumor studies show the drug’s monotherapy potential, with objective response rates […]
MHB048C: A New PSMA-Targeted Therapy for Advanced Solid Tumors
/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxMHB048C is an investigational antibody–drug conjugate designed to target prostate‑specific membrane antigen (PSMA) on tumor cells and selectively deliver a DNA topoisomerase I–inhibiting cytotoxic payload. By combining a PSMA‑directed antibody with a potent payload, the drug aims to exploit the high and relatively restricted expression of this surface antigen in advanced prostate cancer and in […]
Logic-gated DARPins, a Promising Advancement in Immune Therapy for Solid Tumors
/in Not PCa related/by MaxLogic-gated DARPins are a promising new tool in cancer treatment that could make immunotherapy safer and more effective for hard-to-treat solid tumors. They work by only turning on immune cells called T cells when two specific markers are found together on cancer cells, preventing dangerous overactivation in healthy parts of the body. What makes them […]
CONVERT‑HB1: a Phase 2 Trial About Prostate Directed Treatment After Systemic Treatment in mHSPC
/in Clinical Trial, Metastatic, Phase 2/by MaxCONVERT‑HB1 trial addresses a long‑standing uncertainty in metastatic hormone‑sensitive prostate cancer: whether aggressively treating the primary prostate tumor adds meaningful benefit for patients who already have high‑volume metastatic disease and are receiving modern intensified systemic therapy. For years, data from studies like STAMPEDE and HORRAD suggested that local treatment to the prostate might help men […]
UPDATE: ProstACT Global Phase 3 Trial for TLX591 Dosed The First Patient
/in Clinical Trial, Metastatic, Phase 3/by MaxProstACT Global is a pivotal randomized Phase 3 study testing the PSMA-targeted radiopharmaceutical TLX591 (lutetium‑177 rosopatamab tetraxetan) in metastatic castration‑resistant prostate cancer. The trial has just moved into its randomized expansion phase, with the first patient in this part dosed at a specialized prostate cancer center in Melbourne, marking a key transition from safety/dosimetry work […]
UPDATE: TD001 a New Potent ADC for Prostate Cancer Expressing PSMA Enters Phase 1/2
/in Clinical Trial, Metastatic, Phase 1, Phase 2/by MaxTD001, is an investigational antibody-drug conjugate directed against prostate-specific membrane antigen (PSMA), developed for the treatment of men with metastatic castration-resistant prostate cancer whose tumors express PSMA will start recruiting patients for its phase 1/2 clinical trial. Mechanistically, TD001 combines a monoclonal antibody directed against PSMA with a topoisomerase I inhibitor payload, exatecan, linked through […]
PROSTest: Blood mRNA Assay Predicts 177Lu-PSMA Success in mCRPC After One Cycle
/in Retrospective studies/by MaxA study presented at the 2025 Society of Urologic Oncology (SUO) Annual Meeting has introduced PROSTest, a novel blood-based mRNA assay that accurately predicts treatment outcomes for 177Lu-PSMA radioligand therapy in metastatic castration-resistant prostate cancer (mCRPC) patients. The multi-center investigation analyzed 268 PET-positive mCRPC patients from centers in Munster, Basel, and Essen, all with median […]